Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects-Reference-Cited by-同舟云学术

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects

Published:2018-05-24 Issue:7 Volume:18 Page:629-649
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Brandão Mariana¹,Pondé Noam F.¹,Poggio Francesca¹²,Kotecki Nuria¹,Salis Mauren³,Lambertini Matteo¹,de Azambuja Evandro¹

Affiliation:

1. Medical Department, Institut Jules Bordet and L’Université Libre de Bruxelles (U.L.B.), Brussels, Belgium

2. Department of Medical Oncology, Oncologia Medica 2, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genova, Italy

3. Clinical Oncology Department, Hospital Santa Rita, Complexo Hospitalar Irmandade Santa Casa de Misericórdia de Porto Alegre; Rua Sarmento Leite, Porto Alegre, RS, Brazil

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2018.1477596

Reference103 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. HER2-positive breast cancer is lost in translation: time for patient-centered research

3. Survival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015

4. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

5. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Synthesis of Novel 6,7‐Dihydrobenzo[d]isoxazol‐4(5H)‐one Derivatives Bearing 1,2,3‐Triazole Moiety as Potential Hsp90 Inhibitors and their Evaluation as Antiproliferative Agents;ChemistrySelect;2024-03-19

2. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer;Drug Resistance Updates;2024-03

3. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors;European Journal of Clinical Pharmacology;2024-02-11

4. Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer;International Journal of Molecular Sciences;2023-10-12

5. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo;Biological Procedures Online;2023-06-27